Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators

Tomasz M. Beer, Christopher W. Ryan, Peter M. Venner, Daniel P. Petrylak, Gurkamal S. Chatta, J. Dean Ruether, Charles H. Redfern, Louis Fehrenbacher, Mansoor N. Saleh, David M. Waterhouse, Michael A Carducci, Daniel Vicario, Robert Dreicer, Celestia S. Higano, Frederick R. Ahmann, Kim N. Chi, W. David Henner, Alan Arroyo, Fong W. Clow

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later. Results: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%). Conclusion: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.

Original languageEnglish (US)
Pages (from-to)669-674
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number6
DOIs
StatePublished - Feb 20 2007
Externally publishedYes

Fingerprint

docetaxel
Calcitriol
Androgens
Prostatic Neoplasms
Placebos
Research Personnel
Prostate-Specific Antigen
Survival
Neutropenia
Hyperglycemia
Fatigue

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer : A report from the ASCENT investigators. / Beer, Tomasz M.; Ryan, Christopher W.; Venner, Peter M.; Petrylak, Daniel P.; Chatta, Gurkamal S.; Ruether, J. Dean; Redfern, Charles H.; Fehrenbacher, Louis; Saleh, Mansoor N.; Waterhouse, David M.; Carducci, Michael A; Vicario, Daniel; Dreicer, Robert; Higano, Celestia S.; Ahmann, Frederick R.; Chi, Kim N.; Henner, W. David; Arroyo, Alan; Clow, Fong W.

In: Journal of Clinical Oncology, Vol. 25, No. 6, 20.02.2007, p. 669-674.

Research output: Contribution to journalArticle

Beer, TM, Ryan, CW, Venner, PM, Petrylak, DP, Chatta, GS, Ruether, JD, Redfern, CH, Fehrenbacher, L, Saleh, MN, Waterhouse, DM, Carducci, MA, Vicario, D, Dreicer, R, Higano, CS, Ahmann, FR, Chi, KN, Henner, WD, Arroyo, A & Clow, FW 2007, 'Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators', Journal of Clinical Oncology, vol. 25, no. 6, pp. 669-674. https://doi.org/10.1200/JCO.2006.06.8197
Beer, Tomasz M. ; Ryan, Christopher W. ; Venner, Peter M. ; Petrylak, Daniel P. ; Chatta, Gurkamal S. ; Ruether, J. Dean ; Redfern, Charles H. ; Fehrenbacher, Louis ; Saleh, Mansoor N. ; Waterhouse, David M. ; Carducci, Michael A ; Vicario, Daniel ; Dreicer, Robert ; Higano, Celestia S. ; Ahmann, Frederick R. ; Chi, Kim N. ; Henner, W. David ; Arroyo, Alan ; Clow, Fong W. / Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer : A report from the ASCENT investigators. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 6. pp. 669-674.
@article{7eacfd886f8e43d1833c9e3b6d2bda24,
title = "Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators",
abstract = "Purpose: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50{\%} reduction confirmed at least 4 weeks later. Results: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58{\%} in DN-101 patients and 49{\%} in placebo patients (P = .16). Overall, PSA response rates were 63{\%} (DN-101) and 52{\%} (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58{\%} of DN-101 patients and in 70{\%} of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10{\%} v 8{\%}), fatigue (8{\%} v 16{\%}), infection (8{\%} v 13{\%}), and hyperglycemia (6{\%} v 12{\%}). Conclusion: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.",
author = "Beer, {Tomasz M.} and Ryan, {Christopher W.} and Venner, {Peter M.} and Petrylak, {Daniel P.} and Chatta, {Gurkamal S.} and Ruether, {J. Dean} and Redfern, {Charles H.} and Louis Fehrenbacher and Saleh, {Mansoor N.} and Waterhouse, {David M.} and Carducci, {Michael A} and Daniel Vicario and Robert Dreicer and Higano, {Celestia S.} and Ahmann, {Frederick R.} and Chi, {Kim N.} and Henner, {W. David} and Alan Arroyo and Clow, {Fong W.}",
year = "2007",
month = "2",
day = "20",
doi = "10.1200/JCO.2006.06.8197",
language = "English (US)",
volume = "25",
pages = "669--674",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer

T2 - A report from the ASCENT investigators

AU - Beer, Tomasz M.

AU - Ryan, Christopher W.

AU - Venner, Peter M.

AU - Petrylak, Daniel P.

AU - Chatta, Gurkamal S.

AU - Ruether, J. Dean

AU - Redfern, Charles H.

AU - Fehrenbacher, Louis

AU - Saleh, Mansoor N.

AU - Waterhouse, David M.

AU - Carducci, Michael A

AU - Vicario, Daniel

AU - Dreicer, Robert

AU - Higano, Celestia S.

AU - Ahmann, Frederick R.

AU - Chi, Kim N.

AU - Henner, W. David

AU - Arroyo, Alan

AU - Clow, Fong W.

PY - 2007/2/20

Y1 - 2007/2/20

N2 - Purpose: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later. Results: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%). Conclusion: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.

AB - Purpose: To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel. Patients and Methods: Patients with progressive metastatic androgen-independent prostate cancer and adequate organ function received weekly docetaxel 36 mg/m2 intravenously for 3 weeks of a 4-week cycle combined with either 45 μg DN-101 or placebo taken orally 1 day before docetaxel. The primary end point was prostate-specific antigen (PSA) response within 6 months of enrollment, defined as a 50% reduction confirmed at least 4 weeks later. Results: Two hundred fifty patients were randomly assigned. Baseline characteristics were similar in both arms. Within 6 months, PSA responses were seen in 58% in DN-101 patients and 49% in placebo patients (P = .16). Overall, PSA response rates were 63% (DN-101) and 52% (placebo), P = .07. Patients in the DN-101 group had a hazard ratio for death of 0.67 (P = .04) in a multivariate analysis that included baseline hemoglobin and performance status. Median survival has not been reached for the DN-101 arm and is estimated to be 24.5 months using the hazard ratio, compared with 16.4 months for placebo. Grade 3/4 adverse events occurred in 58% of DN-101 patients and in 70% of placebo-treated patients (P = .07). Most common grade 3/4 toxicities for DN-101 versus placebo were neutropenia (10% v 8%), fatigue (8% v 16%), infection (8% v 13%), and hyperglycemia (6% v 12%). Conclusion: This study suggests that DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point. The addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.

UR - http://www.scopus.com/inward/record.url?scp=33947610197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947610197&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.8197

DO - 10.1200/JCO.2006.06.8197

M3 - Article

C2 - 17308271

AN - SCOPUS:33947610197

VL - 25

SP - 669

EP - 674

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -